Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

LSKL, Inhibitor of Thrombospondin (TSP-1)

Product Specifications

UNSPSC Description

LSKL, Inhibitor of Thrombospondin (TSP-1) is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) can readily crosse the blood-brain barrier[1][2].

Target Antigen

TGF-β Receptor

Type

Peptides

Related Pathways

TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/LSKL,_Inhibitor_of_Thrombospondin_TSP-1.html

Purity

99.79

Solubility

DMSO : 100 mg/mL (ultrasonic)|H2O : 50 mg/mL (ultrasonic)

Smiles

CC(C)C[C@@H](C(N)=O)NC([C@H](CCCCN)NC([C@H](CO)NC([C@H](CC(C)C)N)=O)=O)=O

Molecular Weight

458.60

References & Citations

[1]Liao F, et al. LSKL peptide alleviates subarachnoid fibrosis and hydrocephalus by inhibiting TSP1-mediated TGF-β1 signaling activity following subarachnoid hemorrhage in rats. Exp Ther Med. 2016 Oct;12(4):2537-2543. Epub 2016 Aug 31.|[2]Laurent MA, et al. In silico characterization of the interaction between LSKL peptide, a LAP-TGF-beta derived peptide, and ADAMTS1. Comput Biol Chem. 2016 Apr;61:155-61.|[3]Kuroki H, et al. Effect of LSKL peptide on thrombospondin 1-mediated transforming growth factor β signal activation and liver regeneration after hepatectomy in an experimental model. Br J Surg. 2015 Jun;102(7):813-25.Ann Transl Med. 2021 Dec;9(23):1738.|Antioxidants (Basel). 2023 Nov 21, 12(12), 2024.|Cancer Sci. 2024 Jun 28.|Cancers. 2019 Dec 5;11(12):1946.|Cell Tissue Res. 2022 Mar 9.|Environ Pollut. 2020 Apr;259:113915.|PLoS One. 2024 Oct 7;19(10):e0311594.|Sci China Life Sci. 2024 Oct 12.|Cell Death Dis. 2022 Jul 30;13(7):663.|Front Cell Dev Biol. 18 February 2021.|Front Immunol. 2022 Mar 18;13:853894.|J Am Heart Assoc. 2021 Oct 8;e022701.|J Exp Clin Cancer Res. 2022 Aug 26;41(1):259.

Shipping Conditions

Blue Ice

Storage Conditions

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

Product Datasheet

http://file.medchemexpress.com/batch_PDF/HY-P0299/LSKL-Inhibitor-of-Thrombospondin-TSP-1-DataSheet-MedChemExpress.pdf

Product MSDS

http://file.medchemexpress.com/batch_PDF/HY-P0299/LSKL-Inhibitor-of-Thrombospondin-TSP-1-SDS-MedChemExpress.pdf

Clinical Information

No Development Reported

CAS Number

283609-79-0

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

OR3A4 Antibody
E19-10249-2 100ug/100ul

OR3A4 Antibody

Ask
View Details
Ash1l siRNA Oligos set (Rat)
12535176 3 x 5 nmol

Ash1l siRNA Oligos set (Rat)

Ask
View Details
Rabbit Anti-OBSCN antibody
SL21129R-01 50 µL

Rabbit Anti-OBSCN antibody

Ask
View Details
Rabbit Anti-OBSCN antibody
SL21129R-02 100 µL

Rabbit Anti-OBSCN antibody

Ask
View Details
MPP9 CRISPR Activation Plasmid (h)
sc-409772-ACT 20 µg

MPP9 CRISPR Activation Plasmid (h)

Ask
View Details
NMT2 shRNA Plasmid (m)
sc-61135-SH 20 µg

NMT2 shRNA Plasmid (m)

Ask
View Details